Table 1

Baseline characteristics of rituximab-treated patients who received concomitant treatment with methotrexate, leflunomide or no DMARD (rituximab monotherapy)

Baseline characteristics of patientsRituximab plus methotrexate (N=1195)Rituximab plus leflunomide (N=177)Rituximab monotherapy (N=505)ANOVA (overall differences)Pairwise comparisons (t test/χ2)
Age, years (mean±SD)51.9±13.152.3±12.155.2±12.9p<0.0001Methotrexate plus rituximab vs rituximab p<0.0001, Leflunomide plus rituximab vs rituximab p=0.001
N1188177500
Gender (% female)81.383.181.1NSNS
N1194177503
Disease duration, years (mean±SD)11.7±8.811.4±7.913.2±10.1p=0.007Methotrexate plus rituximab vs rituximab p=0.003, Leflunomide plus rituximab vs rituximab p=0.04
N1161169465
No of previous DMARD (mean±SD)2.6±1.52.5±1.42.8±1.8p=0.008Methotrexate plus rituximab vs rituximab p=0.003, Leflunomide plus rituximab vs rituximab p=0.05
N1019162400
No of previous biological agents (mean±SD)0.9±0.80.6±0.81.0±0.8p<0.0001Methotrexate plus rituximab vs rituximab p=0.01, Leflunomide plus rituximab vs rituximab p<0.0001, Methotrexate plus rituximab vs Leflunomide plus rituximab p=0.001
N1136170464
RF (% positive)74.577.678.8NSNS
N1044147415
Anti-CCP (% positive)73.676.176.9NSNS
N44471143
DAS28 (mean±SD)5.9±1.35.9±1.25.7±1.3p=0.029Methotrexate plus rituximab vs rituximab p=0.02
N1108155433
HAQ (mean±SD)1.6±0.71.6±0.71.7±0.7NSNS
N850137323
Use of glucocorticoids (%)59.953.256.6NSNS
N1175171442
Glucocorticoids dose (mg)8.9±7.97.1±5.09.9±10.4p=0.008Methotrexate plus rituximab vs Leflunomide plus rituximab p=0.02, Leflunomide plus rituximab vs rituximab p=0.01
N69699251
  • N=number of patients in each group with available data.

  • ANOVA, analysis of variance; CCP, cyclic citrullinated peptide; DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; HAQ, health assessment questionnaire; RF, rheumatoid factor.